The estimated Net Worth of Jerome M Lewis is at least $1.94 Million dollars as of 31 July 2008. Jerome Lewis owns over 997 units of AMAG Pharmaceuticals stock worth over $1,125 and over the last 17 years Jerome sold AMAG stock worth over $1,935,131.
Jerome has made over 6 trades of the AMAG Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently Jerome sold 997 units of AMAG stock worth $39,880 on 31 July 2008.
The largest trade Jerome's ever made was selling 17,202 units of AMAG Pharmaceuticals stock on 18 January 2008 worth over $1,075,125. On average, Jerome trades about 5,828 units every 22 days since 2007. As of 31 July 2008 Jerome still owns at least 45 units of AMAG Pharmaceuticals stock.
You can see the complete history of Jerome Lewis stock trades at the bottom of the page.
Jerome's mailing address filed with the SEC is C/O AMAG PHARMACEUTICALS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE, MA, 02140.
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C...., and Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include: